▲ 2.97%
prev close
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Congressional Trades
2
All tracked trades
Members Trading
2
Unique members
Net Activity
+2
2 buys · 0 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2026-09-28 | GHGuardant Health, Inc. | Buy | $15,001 - $50,000 | 1d ago | — | |
| 2025-11-21 | GHGuardant Health, Inc. | Buy | $1,001 - $15,000 | 323d ago | — |
2026-09-28
Jonathan Jackson
GH
Amount
$15,001 - $50,000
Filed
1d ago
2025-11-21
Sheldon Whitehouse
GH
Amount
$1,001 - $15,000
Filed
323d ago
Recent News
Powered by Polygon.io
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah
Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight
State of the Life Sciences Industry to Be Reviewed in BCC Research's 2026 Second Quarter Outlook, Spotlighting AI-Driven Discovery, Precision Oncology, and Connected Health Adoption
Trade Timeline
Congressional activity, newest first
Jonathan Jackson
2026-09-28 · Purchase
$15,001 - $50,000
Sheldon Whitehouse
2025-11-21 · Purchase
$1,001 - $15,000